Research

Adicet reports early lupus results for off-the-shelf CAR-T therapy

Endpoints News reported symptom improvement in Adicet’s early lupus study of prula-cel, an off-the-shelf CAR-T therapy.

Reported by 2 outlets Tuesday, September 29, 2026

Bacterial colonies growing in a petri dish
Photo: CC0

Adicet reported early results for prula-cel, an off-the-shelf CAR-T therapy being tested in lupus. The treatment is made from donor cells and uses gamma delta T cells. Endpoints News reported that the therapy improved symptoms in the early-stage study.

BioPharma Dive said the efficacy data were competitive with cell therapies and antibodies, and cited peer cell therapy makers’ complete response rates of about 40%. About a quarter of prula-cel patients experienced mild or moderate CRS. Infections were reported in more than half, and around 8% had infections graded 3 or higher.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.